market growth and opportunity

• Approximately 33 million Americans suffer from overactive bladder (OAB),⁽¹⁾ with prevalence expected to grow significantly as the population ages.
• U.S. prescription sales for genitourinary prescription products (anticholinergic market) in 2007 have been estimated at $1.7 billion, growing at an annual rate of 12 percent.⁽²⁾

Following the 2007 acquisition of Esprit Pharma, Allergan created a dedicated Urologics division to focus on meeting the needs of urologists, urogynecologists and their patients. Recognizing the high unmet need and significant growth potential, Allergan is investing significant resources to develop a product portfolio that addresses the full continuum of care for patients with OAB and other urological and genitourinary disorders. We are currently in Phase III clinical trials investigating the use of BOTOX^® (botulinum toxin type A) for the treatment of neurogenic OAB (OAB secondary to multiple sclerosis, spinal cord injury, or other neurologic dysfunction) and in Phase II clinical trials with BOTOX^® for idiopathic OAB (the most common form of OAB, in which the cause is unknown).

SANCTURA XR™ (trospium Chloride Extended Release Capsules)

In early 2008, Allergan initiated the U.S. launch of SANCTURA XR™, a once-daily medication for the treatment of OAB with symptoms of urge urinary incontinence, urgency and urinary frequency. In clinical studies, SANCTURA XR™ was shown to be effective while significantly reducing dry mouth, a common side effect in this drug class that has been shown to be one of the most common reasons for discontinuation of OAB therapy.⁽³⁾